​BioSculpture Technology, Inc : A Disruptive Treatment of Obesity and Type 2 Diabetes

Spotlight Companies  |

BioSculpture Technology, Inc. is planning an IPO to fund the development of a disruptive treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. Obesity kills thousands of people every month and is one of the leading causes of preventable death in the US. It can bankrupt nations.

We have learned that it is the visceral or “belly” fat within the abdomen which is responsible. Existing surgical options involve significant risks and can create nutritional cripples.The Company obtained three method and device patents for a disruptive solution, Endoscopic Visceral Lipectomy (“EVL”), a minimally invasive procedure to assess which of that belly fat is most noxious and remove it. The company said, "Although safety and efficacy studies are yet to be performed and regulatory approvals obtained, EVL has the potential of doing for obesity treatment what LASIK did for vision correction," said Robert L. Cucin MD JD MBA.

The National Institute of Diabetes and Digestive and Kidney Diseases as well as the Center for Disease Control both confirm that 2/3 of Americans are overweight and 1/3 are obese.1/3 of our children are already obese! McKinsey Global Research projects 50% of the population will be obese and the cost of obesity related diseases will increase to $17 Trillion/year by 2030.

There is growing research that diets and conventional weight-loss methods overwhelming fail. One important reason for this, dieticians believe, is that after a person loses significant weight the body doesn’t understand and works hard to restore the lost weight. Belly fat cells may be emptied of some of their fat contents, but these cells remain, ready to fill up again and secrete the bad cellular hormones which cause hunger, diabetes and hypertension.

Over the years, bariatric surgery has become safer.There are on-average two hundred thousand bariatric surgeries in the United States every year, which creates a $1.3 million market with the potential to rise incrementally every year until $2.0 billion by 2020. Not to mention, Bariatric surgery is reimbursed by most major insurance companies.

One company that is really pushing this industry forward is BioSculpture Technology, Inc. (BST). The company is a commercial-stage medical device manufacturer of medical devices and procedures for handling adipose tissue or fat. BioSculpture has refocused on the bariatric market and is developing a patented, minimally invasive method and device for endoscopic removal of visceral or “belly” fat. This method is expected to be safer than current restrictive or bypass bariatric surgery alternatives, permanent and highly effective.

The company is guided by the inventor of its technology, Dr. Robert L. Cucin, M.D., F.A.C.S. a board-certified plastic surgeon Dr. Cucin received his undergraduate training at Cornell and his M.D. from Cornell’s Medical School. He did both his General Surgery and Plastic & Reconstructive Surgery residences at The New York Hospital - Cornell University Medical Center where he remains on staff. Dr. Cucin is a diplomat of the American Boards of Plastic Surgery, Surgery and Legal Medicine. He has a teaching appointment at the Weill Cornell Medical School.

Dr. Cucin also has a Columbia Business School M.B.A and is a lawyer with aJuris Doctorate from Fordham Law School and is duly admitted to the New York, New Jersey and D.C. BarsMuch of his research has been the subject of numerous contributions to the medical literature and he has published books in the fields of both medicine and law.The rest of the accomplished and talented management and advisory team adds a Harvard Law degree, a Yale M.D, a Ph.D in Mechanical Engineering from Stanford University, and an M.B.A. from Boston University,and even the four stars of a Brigadier General.

BioSculpture has a very lean balance sheet with a projected 84% profit margin on the EVL® device under development. This prototyped and patented device will allow the controlled and safe removal of mesenteric fat for the first time. The thickness of this metabolically noxious mesenteric fat is directly correlated with carotid narrowing and fatty liver, the most severe manifestations of the metabolic syndrome which accompanies obesity in up to 50% of patients.

The surgeon will insert the laparoscopic device with its patented, gentle aspirator into tiny incisions in the patients belly area. Patients who would be ideal for this procedure are at a known high risk for diabetes. Because of its patented design, the EVL® device allows the removal of this metabolically noxious “belly” fat in a controlled and safe fashion without the need of manual stroking.

EVL®BioSculpture Technology, Inc.

After the proposed procedure, it is anticipated the patients will be at a lower risk for diabetes and will lose body fat in a ratio of 7-10 times that of the 6-9 pounds belly fat removed or a 40-90 pounds within an estimated 4-6 months. Since this removed fat secretes noxious cellular hormones that cause hypertension and lower the metabolism, its removal will favorably impact the patients metabolism immediately at the time of surgery. As this procedure does not involve cutting into the bowel or stomach, rearranging the body’s alimentary plumbing or leaving behind a foreign body as do the other bariatric surgical alternatives, it is “safer by design” than the alternative procedures as it exposes the patient to fewer potential risks and complications. It is anticipated the minimally invasive procedure may be repeated as needed until the ideal weight has been achieved.

The Company has an IPO to fund development and clinical testing of the EVL® device and procedure. Although safety and efficacy studies are yet to be performed, and regulatory approvals obtained, the company believes EVL® has the potential to do for obesity treatment what LASIK did for vision correction.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated in cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.


Symbol Last Price Change % Change